SCHEMBL4048676

SCHEMBL4048676

CCc1ccc(S(=O)(=O)O)cc1.CSc1nc(-c2ccccc2)cs1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PHGDH O43175 1/20 0.48
L3MBTL1 Q9Y468 2/20 0.47
TP53 P04637 1/20 0.47
TSHR P16473 1/20 0.47
MCL1 Q07820 1/20 0.47
RORC P51449 1/20 0.47
RAB9A P51151 6/20 0.46
NPC1 O15118 5/20 0.46
TDP1 Q9NUW8 1/20 0.46
MAPT P10636 5/20 0.44
PKM P14618 2/20 0.44
SMN1; SMN2 Q16637 1/20 0.43
MEN1 O00255 5/20 0.43
KMT2A Q03164 5/20 0.43
LMNA P02545 2/20 0.43
MAPK1 P28482 2/20 0.43
HTR1A P08908 1/20 0.43
HTR2A P28223 1/20 0.43
HTR7 P34969 1/20 0.43
HTT P42858 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4050004 0.89 RORC (0.48) TSHRRORCRAB9ANPC1MAPT
SCHEMBL4050954 0.87 LTA4H (0.46) RAB9ANPC1MAPTPKMSMN1; SMN2
SCHEMBL4050455 0.82 ALDH1A1 (0.40) MAPTPKMSMN1; SMN2MEN1KMT2A
SCHEMBL4048678 0.81 PHGDH (0.46) PHGDHRAB9ANPC1TDP1MAPT
SCHEMBL4047725 0.78 HTR1A (0.58) RAB9ANPC1TDP1MAPTSMN1; SMN2
SCHEMBL4050605 0.76 ALDH1A1 (0.49) TSHRRAB9ANPC1MAPTPKM
SCHEMBL11705732 0.75 RAB9A (0.58) RAB9ANPC1TDP1MAPTSMN1; SMN2
SCHEMBL4048668 0.74 MEN1 (0.42) PHGDHRAB9ANPC1TDP1MAPT
SCHEMBL10446679 0.73 SMN1; SMN2 (0.64) L3MBTL1TP53TSHRRAB9ANPC1
SCHEMBL4051285 0.73 FBP1 (0.39) L3MBTL1TP53MAPTPKMKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090247579-A1 2-[3H-THIAZOL-2-YLIDINEMETHYL]PYRIDINES AND RELATED COMPOUNDS AND THEIR USE CANCER RESEARCH TECHNOLOGY LIMITED 2009-10-01 US disclosed
EP-2029584-A2 2-[3H-THIAZOL-2-YLIDINEMETHYL]PYRIDINES AND RELATED COMPOUNDS AND THEIR USE Cancer Research Technology Limited (GB) 2009-03-04 EP disclosed
WO-2007096618-A2 2-[3H-THIAZOL-2-YLIDINEMETHYL]PYRIDINES AND RELATED COMPOUNDS AND THEIR USE CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2007-08-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090247579-A1 2-[3H-THIAZOL-2-YLIDINEMETHYL]PYRIDINES AND RELATED COMPOUNDS AND THEIR USE RB1, RBBP5, RRM2B PHGDH 3658/4885L3MBTL1 1828/4885TP53 20/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.